Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. - Wikidata - wikimedia - TriplyDB

Rituximab therapy in idiopathic membranous nephropathy: a 2-year study.

Rituximab therapy in idiopathic membranous nephropathy: a 2-year study.

http://www.wikidata.org/entity/Q34362660

about

Management of Membranous Nephropathy in Western Countries Management of Membranous Nephropathy in Asia Alternative Pathway Dysregulation and the Conundrum of Complement Activation by IgG4 Immune Complexes in Membranous Nephropathy Triggers, bullets and targets, puzzle of membranous nephropathy.B cell-depleting therapy with rituximab or ofatumumab in immunoglobulin A nephropathy or vasculitis with nephritis.Infusion of autologous bone marrow mononuclear cells leads to transient reduction in proteinuria in treatment refractory patients with Idiopathic membranous nephropathy.Current therapy of granulomatosis with polyangiitis and microscopic polyangiitis: the role of rituximab Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy Rituximab treatment for membranous nephropathy: a French clinical and serological retrospective study of 28 patients.IgG4-Related Disease Is Not Associated with Antibody to the Phospholipase A2 Receptor.Rituximab in Children with Steroid-Dependent Nephrotic Syndrome: A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial.A European multicentre and open-label controlled randomized trial to evaluate the efficacy of Sequential treatment with TAcrolimus-Rituximab versus steroids plus cyclophosphamide in patients with primary MEmbranous Nephropathy: the STARMEN study.Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy Pharmacological treatment of primary membranous nephropathy in 2016.Rituximab in idiopathic membranous nephropathy.Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series.Treatment of idiopathic membranous nephropathy.Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial Low- and high-molecular-weight urinary proteins as predictors of response to rituximab in patients with membranous nephropathy: a prospective study.A Patient with Abnormal Kidney Function and a Monoclonal Light Chain in the Urine.Effective treatment with rituximab for the maintenance of remission in frequently relapsing minimal change disease.Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody-mediated disease.Membranous nephropathy: Pilot study of a novel regimen combining cyclosporine and Rituximab.Experience with rituximab in the treatment of antineutrophil cytoplasmic antibody associated vasculitis A novel link: in children, cow milk processing may be causative of idiopathic membranous nephropathy.Update on the role of rituximab in kidney diseases and transplant.Membranous nephropathy: the start of a paradigm shift.Our experience with rituximab therapy for adult-onset primary glomerulonephritis and review of literature.Rituximab: emerging treatment strategies of immune-mediated glomerular disease.Rituximab therapy in nephrotic syndrome: implications for patients' management.New diagnostic tests and new therapies for glomerular diseases.Glomerular diseases: membranous nephropathy--a modern view B-cell-targeted therapy in adult glomerulonephritis.B cell depletion: rituximab in glomerular disease and transplantation Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review.Overview of current and alternative therapies for idiopathic membranous nephropathy.Biologic agents in the treatment of glomerulonephritides.Monoclonal antibodies for renal diseases: current concepts and ongoing treatments.Membranous nephropathy: thinking through the therapeutic options.Biologics for the treatment of autoimmune renal diseases.

P2860

Q26740477-4857A105-C156-46C6-94F7-538ECB32169C Q26740481-AD177CA2-B1E7-4230-8EAE-48FA54C5BF59 Q26747416-1FDE55CE-EA7B-4921-A27F-8806499BAB01 Q33355637-E02E1494-403D-42F2-93E3-61A8313BA020 Q33793476-371A87B6-96B8-4649-9D9E-721011DE5AB4 Q34448821-D87AFA3C-7C4C-41A0-8E9F-BE21DB7D6EE7 Q35065425-0061BAB0-D946-4406-90DD-3A5848B44833 Q35142743-B8B53140-51C9-475D-991A-2736B7953DBB Q35791799-2AE46BA1-D4E7-4239-B18F-2BE81039EB09 Q35979027-4391EEC9-C422-4AB8-B7AA-8EA775379D44 Q36003160-648253F8-AB36-4206-8516-4236B3EFAC27 Q36088887-8990915C-273A-4E63-8A58-4741AC5119FE Q36104805-A5C12801-B567-44E4-A39B-E82D54EA8880 Q36106413-5A3FE318-8C11-4ECA-B8D2-1F136F81A64C Q36109197-AB5E6A10-1A79-400A-996C-E47D063F38A3 Q36265388-4D769DCF-CE62-402D-B4D5-1D62956E6905 Q36280345-FB8564E7-CC48-4961-8870-0956974B8F43 Q36662933-CF5A0C15-0FE8-45C2-9E74-533F02E69225 Q36741001-A61D3B7D-EF66-4829-80AB-144B809875EF Q36965127-DA87DC41-F289-4BB4-8EBA-54C3E0842498 Q37261621-72D64DBF-EA1D-4D03-ADC5-D9EAA0E29456 Q37369319-6AB6BE4E-186E-4313-892B-5F07F631FD52 Q37475696-AB386A67-C65D-420D-BE42-552823B3B69F Q37640836-7ADA763B-FAF6-46C4-8EC7-7454E1A989C8 Q37970010-374BEFD4-9AE9-4B0B-A03E-15110989C5EB Q37970443-C948D168-6998-41C9-A73C-E420B3618743 Q37975360-1F87811D-58E1-4CF1-8CAF-83CBC16450E4 Q38026511-580BC3FE-19B0-40C7-B456-4BCD7F356A66 Q38033648-BC72C86D-AD5C-422B-9D0C-172640117FDF Q38075787-C3D08A41-6E76-48AD-986F-964EE5D0F55B Q38076221-D5C6103D-E26E-4AF0-B076-58A7471AE8B8 Q38118221-A7B10BF0-C155-4DED-856E-BABA57D8FC99 Q38159787-1D057174-BBF1-4656-A0EE-3B915F8CA0C7 Q38189360-9D64C2BA-926F-45D7-A828-FDDC128520C3 Q38206050-35311581-833A-480E-85A4-417D5C8B045C Q38425865-CC19B1C5-1226-4638-8E9A-1243250BBAA4 Q38514894-E5717C92-60C7-4700-98D5-5DEA84B35C80 Q38531349-08F47E37-9997-48E7-940C-F49E777AC39C Q38733002-2133E307-46C1-436D-9E95-12CACAE7B43D Q38763327-4D1BE370-5B85-423D-94EB-53A90D1EB2CD

P2860

Rituximab therapy in idiopathic membranous nephropathy: a 2-year study.

http://www.wikidata.org/entity/Q34362660

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Rituximab therapy in idiopathic membranous nephropathy: a 2-year study.

@ast

Rituximab therapy in idiopathic membranous nephropathy: a 2-year study.

@en

Rituximab therapy in idiopathic membranous nephropathy: a 2-year study.

@nl

type

label

Rituximab therapy in idiopathic membranous nephropathy: a 2-year study.

@ast

Rituximab therapy in idiopathic membranous nephropathy: a 2-year study.

@en

Rituximab therapy in idiopathic membranous nephropathy: a 2-year study.

@nl

prefLabel

Rituximab therapy in idiopathic membranous nephropathy: a 2-year study.

@ast

Rituximab therapy in idiopathic membranous nephropathy: a 2-year study.

@en

Rituximab therapy in idiopathic membranous nephropathy: a 2-year study.

@nl

P1433

Q34362660-74B3DABE-0A79-4FDB-B146-B94C044748E1

P1476

Q34362660-E331FEC8-154E-4EFB-B5E2-73EAB1F20488

P2093

Q34362660-0DC67C32-D7F4-40DE-97BD-532225B337D4

Q34362660-0DEEB248-7CF1-4261-9AF5-547586EABDD6

Q34362660-0ECBECAC-8C50-49BC-A087-4E7A99FF6BFE

Q34362660-22401B7C-1024-4716-9CDB-DD5D125F48BB

Q34362660-228D0729-D3E3-4CA5-A87A-4FEEC733985B

Q34362660-2571166E-926A-468E-AF64-B5258E9B883D

Q34362660-7FAB8A51-B4B6-4D59-9EA7-996582E9CBB7

Q34362660-8923B666-ADA3-4E15-892B-E1392FB25280

Q34362660-9781C8B2-5287-4724-87E1-95DCC6B91B83

Q34362660-98D4301B-966D-4B56-9569-82E6C9778062

P2860

Q34362660-02727281-C4B3-4BBD-BBFB-9498C129B554

Q34362660-16BDE8E6-68A3-4DE1-8EFE-95C2634F392B

Q34362660-22174810-138C-4632-9ED1-AC1A811FF6F4

Q34362660-2AA0E946-53D8-4805-823A-C8EE9E6BB80B

Q34362660-3847D284-3322-4CE1-A8E0-1C819EC0F733

Q34362660-592E48C9-E357-4309-98B6-C6B452C71732

Q34362660-6251C7D2-771A-48EC-9A4F-7AA9446E7108

Q34362660-7F5B531F-25C2-4FBF-A16D-1AECA7FDF6A3

Q34362660-87BC19DB-6FDC-400F-9569-21A5BE92B746

Q34362660-971B1B7D-E7B5-4293-A18A-61EBF396917F

P304

Q34362660-7CF869D3-3005-4853-8DB1-E8C8B9CC70F0

P31

Q34362660-848E7B00-5311-4C1B-A948-48503CF430B9

P356

Q34362660-D04DF5D1-BC5A-4FC7-974D-8B695486EECD

P433

Q34362660-9E6567C7-474C-4585-BD97-6D40AD38FE90

P478

Q34362660-CD507A5C-284F-44F7-B3E8-FE28DB02C277

P577

Q34362660-43947D2D-9D68-4423-9D21-6F6166A802F9

P698

Q34362660-AB329FB8-FEF5-4682-8496-280F10081552

P932

Q34362660-7C333DB3-5EB7-4A37-AC79-87C2C2F266DD

P356

P1433

Clinical Journal of the American Society of Nephrology

P1476

Rituximab therapy in idiopathic membranous nephropathy: a 2-year study.

@en

P2093

Alfonso Eirin

http://www.w3.org/2001/XMLSchema#string

Daniel C Cattran

http://www.w3.org/2001/XMLSchema#string

Eric J Bergstralh

http://www.w3.org/2001/XMLSchema#string

Fernando C Fervenza

http://www.w3.org/2001/XMLSchema#string

Fernando G Cosio

http://www.w3.org/2001/XMLSchema#string

John J Dillon

http://www.w3.org/2001/XMLSchema#string

LaTonya J Hickson

http://www.w3.org/2001/XMLSchema#string

Maria Valentina Irazabal

http://www.w3.org/2001/XMLSchema#string

Marie C Hogan

http://www.w3.org/2001/XMLSchema#string

Mayo Nephrology Collaborative Group

http://www.w3.org/2001/XMLSchema#string

P2860

Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial.

Management of membranous nephropathy: when and what for treatment.

A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy.

Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy

Selective effects of cyclophosphamide therapy on activation, proliferation, and differentiation of human B cells.

Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism

Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future.

Drug insight: rituximab in renal disease and transplantation.

Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment.

Rituximab in idiopathic membranous nephropathy: a one-year prospective study.

P304

2188-2198

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2215/CJN.05080610

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2010-08-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20705965

http://www.w3.org/2001/XMLSchema#string

P932

2994079

http://www.w3.org/2001/XMLSchema#string